Mitsubishi UFJ Asset Management
KRYS icon

Mitsubishi UFJ Asset Management’s Krystal Biotech KRYS Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$284K Sell
764
-383
-33% -$114K ﹤0.01% 973
2026
Q1 		$296K Sell
1,147
-28
-2% -$7.45K ﹤0.01% 924
2025
Q4 		$290K Sell
1,175
-623
-35% -$131K ﹤0.01% 961
2025
Q3 		$317K Buy
1,798
+3
+0.2% +$449 ﹤0.01% 939
2025
Q2 		$247K Buy
1,795
+303
+20% +$44.5K ﹤0.01% 952
2025
Q1 		$269K Buy
1,492
+125
+9% +$21K ﹤0.01% 918
2024
Q4 		$216K Sell
1,367
-210
-13% -$37.3K ﹤0.01% 978
2024
Q3 		$287K Sell
1,577
-149
-9% -$28.7K ﹤0.01% 920
2024
Q2 		$317K Sell
1,726
-517
-23% -$86.8K ﹤0.01% 911
2024
Q1 		$399K Sell
2,243
-102
-4% -$14.2K ﹤0.01% 897
2023
Q4 		$279K Sell
2,345
-662
-22% -$73.4K ﹤0.01% 977
2023
Q3 		$349K Buy
3,007
+283
+10% +$34.5K ﹤0.01% 968
2023
Q2 		$320K Sell
2,724
-752
-22% -$76.8K ﹤0.01% 982
2023
Q1 		$278K Buy
3,476
+227
+7% +$17.8K ﹤0.01% 986
2022
Q4 		$257K Sell
3,249
-1,179
-27% -$87.5K ﹤0.01% 998
2022
Q3 		$309K Buy
4,428
+72
+2% +$5.2K ﹤0.01% 972
2022
Q2 		$286K Sell
4,356
-1,845
-30% -$115K ﹤0.01% 999
2022
Q1 		$413K Buy
6,201
+285
+5% +$17.8K ﹤0.01% 969
2021
Q4 		$427K Buy
5,916
+1,186
+25% +$69K ﹤0.01% 972
2021
Q3 		$247K Buy
4,730
+129
+3% +$7.64K ﹤0.01% 1031
2021
Q2 		$313K Sell
4,601
-3,971
-46% -$277K ﹤0.01% 1033
2021
Q1 		$660K Buy
8,572
+2,764
+48% +$201K ﹤0.01% 846
2020
Q4 		$348K Buy
5,808
+2,222
+62% +$111K ﹤0.01% 872
2020
Q3 		$154K Buy
3,586
+11
+0.3% +$478 ﹤0.01% 924
2020
Q2 		$148K Buy
3,575
+241
+7% +$11.6K ﹤0.01% 923
2020
Q1 		$144K Buy
3,334
+695
+26% +$36.4K ﹤0.01% 892
2019
Q4 		$157K Buy
+2,639
New +$129K ﹤0.01% 910

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Mitsubishi UFJ Asset Management's KRYS Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management reduced its Krystal Biotech (KRYS) stake by 33% in Q2 2026, selling an estimated $114K and leaving 764 shares worth $284K. The position accounts for ﹤0.01% of the portfolio, ranked #973.

Mitsubishi UFJ Asset Management first reported a position in KRYS in Q4 2019 and has held it in 27 quarters since. The position peaked at $660K in Q1 2021. 422 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Mitsubishi UFJ Asset Management held 764 shares of Krystal Biotech worth $284K as of Q2 2026.
  • Mitsubishi UFJ Asset Management sold 383 Krystal Biotech shares in Q2 2026, an estimated $114K.
  • Krystal Biotech made up ﹤0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #973 holding.
  • Mitsubishi UFJ Asset Management first reported a position in Krystal Biotech in Q4 2019 and has held it in 27 quarters since.
  • Mitsubishi UFJ Asset Management's Krystal Biotech position peaked at $660K in Q1 2021.
  • 422 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.